Developmental origins of fusion-negative rhabdomyosarcomas

Current Topics in Developmental Biology

Volumn 96, Issue , 2011, Pages 33-56

  Kikuchi, Ken ^a   Rubin, Brian P ^b,c   Keller, Charles ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Embryonal Rhabdomyosarcoma; Muscle; Myogenesis; Rhabdomyosarcoma; Satellite Cell; Stem cell

Indexed keywords

ANIMAL; BOOK; CANCER STEM CELL; CELL TRANSFORMATION; CYTOLOGY; GENETICS; HUMAN; PATHOLOGY; PHENOTYPE; RHABDOMYOSARCOMA;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASTIC STEM CELLS; PHENOTYPE; RHABDOMYOSARCOMA;

EID: 79957482304     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385940-2.00002-4     Document Type: Book

References (97)

1. Andrechek E.R., Hardy W.R., Girgis-Gabardo A.A., Perry R.L., Butler R., Graham F.L., Kahn R.C., Rudnicki M.A., Muller W.J. ErbB2 is required for muscle spindle and myoblast cell survival. Mol. Cell. Biol. 2002, 22:4714-4722.
2. Beauchamp J.R., Heslop L., Yu D.S., Tajbakhsh S., Kelly R.G., Wernig A., Buckingham M.E., Partridge T.A., Zammit P.S. Expression of CD34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J. Cell Biol. 2000, 151:1221-1234.
3. Bomken S., Fiser K., Heidenreich O., Vormoor J. Understanding the cancer stem cell. Br. J. Cancer 2010, 103:439-445.
4. Borden E.C., Baker L.H., Bell R.S., Bramwell V., Demetri G.D., Eisenberg B.L., Fletcher C.D., Fletcher J.A., Ladanyi M., Meltzer P., O'Sullivan B., Parkinson D.R., et al. Soft tissue sarcomas of adults: State of the translational science. Clin. Cancer Res. 2003, 9:1941-1956.
5. Breneman J.C., Lyden E., Pappo A.S., Link M.P., Anderson J.R., Parham D.M., Qualman S.J., Wharam M.D., Donaldson S.S., Maurer H.M., Meyer W.H., Baker K.S., et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-A report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 2003, 21:78-84.
6. Bridge J.A., Liu J., Weibolt V., Baker K.S., Perry D., Kruger R., Qualman S., Barr F., Sorensen P., Triche T., Suijkerbuijk R. Novel genomic imbalances in embryonal rhabdomyosarcoma revealed by comparative genomic hybridization and fluorescence in situ hybridization: An intergroup rhabdomyosarcoma study. Genes Chromosomes Cancer 2000, 27:337-344.
7. Brown C.B., Engleka K.A., Wenning J., Min Lu M., Epstein J.A. Identification of a hypaxial somite enhancer element regulating Pax3 expression in migrating myoblasts and characterization of hypaxial muscle Cre transgenic mice. Genesis 2005, 41:202-209.
8. Calzada-Wack J., Kappler R., Schnitzbauer U., Richter T., Nathrath M., Rosemann M., Wagner S.N., Hein R., Hahn H. Unbalanced overexpression of the mutant allele in murine patched mutants. Carcinogenesis 2002, 23:727-733.
9. Chen L., Shah H.O., Lin J.H. Alveolar rhabdomyosarcoma with concurrent metastases to bone marrow and lymph nodes simulating acute hematologic malignancy. J. Pediatr. Hematol. Oncol. 2004, 26:696-697.
10. Chen Y., Takita J., Hiwatari M., Igarashi T., Hanada R., Kikuchi A., Hongo T., Taki T., Ogasawara M., Shimada A., Hayashi Y. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies. Genes Chromosomes Cancer 2006, 45:583-591.
11. Clark M.A., Fisher C., Judson I., Thomas J.M. Soft-tissue sarcomas in adults. N. Engl. J. Med. 2005, 353:701-711.
12. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 2006, 66:9339-9344.
13. Cornelison D.D., Wold B.J. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol. 1997, 191:270-283.
14. Davicioni E., Anderson M.J., Finckenstein F.G., Lynch J.C., Qualman S.J., Shimada H., Schofield D.E., Buckley J.D., Meyer W.H., Sorensen P.H., Triche T.J. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am. J. Pathol. 2009, 174:550-564.
15. De Chiara A., T'Ang A., Triche T.J. Expression of the retinoblastoma susceptibility gene in childhood rhabdomyosarcomas. J. Natl. Cancer Inst. 1993, 85:152-157.
16. Diller L., Sexsmith E., Gottlieb A., Li F.P., Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J. Clin. Invest. 1995, 95:1606-1611.
17. Doyle B., Morton J.P., Delaney D.W., Ridgway R.A., Wilkins J.A., Sansom O.J. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J. Pathol. 2010, 222:129-137.
18. Felix C.A., Kappel C.C., Mitsudomi T., Nau M.M., Tsokos M., Crouch G.D., Nisen P.D., Winick N.J., Helman L.J. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 1992, 52:2243-2247.
19. Ferrari A., Bisogno G., Macaluso A., Casanova M., D'Angelo P., Pierani P., Zanetti I., Alaggio R., Cecchetto G., Carli M. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer 2007, 109:1406-1412.
20. Fleischmann A., Jochum W., Eferl R., Witowsky J., Wagner E.F. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: Tumor suppression by the Fos protooncogene. Cancer Cell 2003, 4:477-482.
21. Frank K.M., Sharpless N.E., Gao Y., Sekiguchi J.M., Ferguson D.O., Zhu C., Manis J.P., Horner J., DePinho R.A., Alt F.W. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol. Cell 2000, 5:993-1002.
22. Fukada S., Uezumi A., Ikemoto M., Masuda S., Segawa M., Tanimura N., Yamamoto H., Miyagoe-Suzuki Y., Takeda S. Molecular signature of quiescent satellite cells in adult skeletal muscle. Stem Cells 2007, 25:2448-2459.
23. Gil-Benso R., Lopez-Gines C., Carda C., Lopez-Guerrero J.A., Ferrer J., Pellin-Perez A., Llombart-Bosch A. Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases. Cancer Genet. Cytogenet. 2003, 144:125-133.
24. Gorlin R.J. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet. Med. 2004, 6:530-539.
25. Grigoriadis A.E., Schellander K., Wang Z.Q., Wagner E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 1993, 122:685-701.
26. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., Wagner E.F. c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
27. Gripp K.W. Tumor predisposition in Costello syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 2005, 137C:72-77.
28. Gripp K.W., Lin A.E. Costello Syndrome. GeneReviews at GeneTests: Medical Genetics Information 2009, Copyright, University of Washington, Seattle, Resource (database online) 1993-2011. Available at, Accessed March 21, 2011. http://www.genetests.org.
29. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: Mirage or reality?. Nat. Med. 2009, 15:1010-1012.
30. Guthridge M., Wilson M., Cowling J., Bertolini J., Hearn M.T. The role of basic fibroblast growth factor in skeletal muscle regeneration. Growth Factors 1992, 6:53-63.
31. Hahn H., Wojnowski L., Zimmer A.M., Hall J., Miller G., Zimmer A. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 1998, 4:619-622.
32. Haldar M., Karan G., Tvrdik P., Capecchi M.R. Two cell lineages, myf5 and myf5-independent, participate in mouse skeletal myogenesis. Dev. Cell 2008, 14:437-445.
33. Hall B.K., Miyake T. All for one and one for all: Condensations and the initiation of skeletal development. Bioessays 2000, 22:138-147.
34. Harvey M., McArthur M.J., Montgomery C.A., Bradley A., Donehower L.A. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993, 7:938-943.
35. Harvey M., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat. Genet. 1993, 5:225-229.
36. Hirotsu M., Setoguchi T., Matsunoshita Y., Sasaki H., Nagao H., Gao H., Sugimura K., Komiya S. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br. J. Cancer 2009, 101:2030-2037.
37. Iolascon A., Faienza M.F., Coppola B., Rosolen A., Basso G., Della Ragione F., Schettini F. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer 1996, 15:217-222.
38. Ireland H., Kemp R., Houghton C., Howard L., Clarke A.R., Sansom O.J., Winton D.J. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: Effect of loss of beta-catenin. Gastroenterology 2004, 126:1236-1246.
39. Jessen J.R., Jessen T.N., Vogel S.S., Lin S. Concurrent expression of recombination activating genes 1 and 2 in zebrafish olfactory sensory neurons. Genesis 2001, 29:156-162.
40. Keleti J., Quezado M.M., Abaza M.M., Raffeld M., Tsokos M. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. Am. J. Pathol. 1996, 149:143-151.
41. Keller C., Arenkiel B.R., Coffin C.M., El-Bardeesy N., DePinho R.A., Capecchi M.R. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 2004, 18:2614-2626.
42. Kleinerman R.A., Tucker M.A., Abramson D.H., Seddon J.M., Tarone R.E., Fraumeni J.F. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J. Natl. Cancer Inst. 2007, 99:24-31.
43. Kohashi K., Oda Y., Yamamoto H., Tamiya S., Takahira T., Takahashi Y., Tajiri T., Taguchi T., Suita S., Tsuneyoshi M. Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: Special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J. Cancer Res. Clin. Oncol. 2008, 134:1097-1103.
44. Komuro H., Saihara R., Shinya M., Takita J., Kaneko S., Kaneko M., Hayashi Y. Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines. J. Pediatr. Surg. 2007, 42:2040-2045.
45. Koufos A., Hansen M.F., Copeland N.G., Jenkins N.A., Lampkin B.C., Cavenee W.K. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985, 316:330-334.
46. Kuang S., Kuroda K., Le Grand F., Rudnicki M.A. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell 2007, 129:999-1010.
47. Lagha M., Brunelli S., Messina G., Cumano A., Kume T., Relaix F., Buckingham M.E. Pax3:Foxc2 reciprocal repression in the somite modulates muscular versus vascular cell fate choice in multipotent progenitors. Dev. Cell 2009, 17:892-899.
48. Lam S.H., Wu Y.L., Vega V.B., Miller L.D., Spitsbergen J., Tong Y., Zhan H., Govindarajan K.R., Lee S., Mathavan S., Murthy K.R., Buhler D.R., et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat. Biotechnol. 2006, 24:73-75.
49. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-872.
50. Langenau D.M., Keefe M.D., Storer N.Y., Guyon J.R., Kutok J.L., Le X., Goessling W., Neuberg D.S., Kunkel L.M., Zon L.I. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev. 2007, 21:1382-1395.
51. Le Bihan C., Moutou C., Brugieres L., Feunteun J., Bonaiti-Pellie C. ARCAD: A method for estimating age-dependent disease risk associated with mutation carrier status from family data. Genet. Epidemiol. 1995, 12:13-25.
52. Lee Y., Miller H.L., Russell H.R., Boyd K., Curran T., McKinnon P.J. Patched2 modulates tumorigenesis in patched1 heterozygous mice. Cancer Res. 2006, 66:6964-6971.
53. Lefaucheur J.P., Sebille A. Basic fibroblast growth factor promotes in vivo muscle regeneration in murine muscular dystrophy. Neurosci. Lett. 1995, 202:121-124.
54. Linardic C.M., Downie D.L., Qualman S., Bentley R.C., Counter C.M. Genetic modeling of human rhabdomyosarcoma. Cancer Res. 2005, 65:4490-4495.
55. Lisboa S., Cerveira N., Vieira J., Torres L., Ferreira A.M., Afonso M., Norton L., Henrique R., Teixeira M.R. Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatr. Blood Cancer 2008, 51:554-557.
56. Lohmann D.R., Gallie B.L. Retinoblastoma. GeneReviews at GeneTests: Medical Genetics Information 2010, Resource (database online), Copyright, University of Washington, Seattle, 1993-2011. Available at, Accessed March 21, 2011. http://www.genetests.org.
57. Maric D., Fiorio Pla A., Chang Y.H., Barker J.L. Self-renewing and differentiating properties of cortical neural stem cells are selectively regulated by basic fibroblast growth factor (FGF) signaling via specific FGF receptors. J. Neurosci. 2007, 27:1836-1852.
58. Martinelli S., McDowell H.P., Vigne S.D., Kokai G., Uccini S., Tartaglia M., Dominici C. RAS signaling dysregulation in human embryonal rhabdomyosarcoma. Genes Chromosomes Cancer 2009, 48:975-982.
59. Merlino G., Khanna C. Fishing for the origins of cancer. Genes Dev. 2007, 21:1275-1279.
60. Messina G., Sirabella D., Monteverde S., Galvez B.G., Tonlorenzi R., Schnapp E., De Angelis L., Brunelli S., Relaix F., Buckingham M., Cossu G. Skeletal muscle differentiation of embryonic mesoangioblasts requires pax3 activity. Stem Cells 2009, 27:157-164.
61. Miyachi M., Kakazu N., Yagyu S., Katsumi Y., Tsubai-Shimizu S., Kikuchi K., Tsuchiya K., Iehara T., Hosoi H. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin. Cancer Res. 2009, 15:4077-4084.
62. Moschovi M., Touliatou V., Papadopoulou A., Mayakou M.A., Nikolaidou-Karpathiou P., Kitsiou-Tzeli S. Rhabdomyosarcoma in a patient with Noonan syndrome phenotype and review of the literature. J. Pediatr. Hematol. Oncol. 2007, 29:341-344.
63. Nanni P., Nicoletti G., De Giovanni C., Croci S., Astolfi A., Landuzzi L., Di Carlo E., Iezzi M., Musiani P., Lollini P.L. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Res. 2003, 63:2728-2732.
64. Nishijo K., Hosoyama T., Bjornson C.R., Schaffer B.S., Prajapati S.I., Bahadur A.N., Hansen M.S., Blandford M.C., McCleish A.T., Rubin B.P., Epstein J.A., Rando T.A., et al. Biomarker system for studying muscle, stem cells, and cancer in vivo. FASEB J. 2009, 23:2681-2690.
65. Odelberg S.J., Kollhoff A., Keating M.T. Dedifferentiation of mammalian myotubes induced by msx1. Cell 2000, 103:1099-1109.
66. Olivier M., Goldgar D.E., Sodha N., Ohgaki H., Kleihues P., Hainaut P., Eeles R.A. Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003, 63:6643-6650.
67. Oue T., Yoneda A., Uehara S., Yamanaka H., Fukuzawa M. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J. Pediatr. Surg. 2010, 45:387-392.
68. Parham D.M., Ellison D.A. Rhabdomyosarcomas in adults and children: An update. Arch. Pathol. Lab. Med. 2006, 130:1454-1465.
69. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
70. Relaix F., Montarras D., Zaffran S., Gayraud-Morel B., Rocancourt D., Tajbakhsh S., Mansouri A., Cumano A., Buckingham M. Pax3 and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J. Cell Biol. 2006, 172:91-102.
71. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
72. Ricci C., Landuzzi L., Rossi I., De Giovanni C., Nicoletti G., Astolfi A., Pupa S., Menard S., Scotlandi K., Nanni P., Lollini P.L. Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int. J. Cancer 2000, 87:29-36.
73. Rubin B.P., Nishijo K., Chen H.-I.H., Yi X., Schuetze D.P., Pal R., Prajapati S.I., Abraham J., Arenkiel B.R., Chen Q.-R., Davis S., McCleish A.T., et al. Evidence for an unanticipated relationship between undifferentiated pleomorphic sarcoma and embryonal rhabdomyosarcoma. Cancer Cell 2011, 19:177-791.
74. Sandberg A.A., Stone J.F., Czarnecki L., Cohen J.D. Hematologic masquerade of rhabdomyosarcoma. Am. J. Hematol. 2001, 68:51-57.
75. Sansom O.J., Griffiths D.F., Reed K.R., Winton D.J., Clarke A.R. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 2005, 24:8205-8210.
76. Schneider K., Garber J. Li-Fraumeni Syndrome. GeneReviews at GeneTests: Medical Genetics Information 2010, Resource (database online), Copyright, University of Washington, Seattle, 1993-2011. Available at Accessed March 21, 2011. http://www.genetests.org.
77. Scrable H., Cavenee W., Ghavimi F., Lovell M., Morgan K., Sapienza C. A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc. Natl. Acad. Sci. USA 1989, 86:7480-7484.
78. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37.
79. Sharp R., Recio J.A., Jhappan C., Otsuka T., Liu S., Yu Y., Liu W., Anver M., Navid F., Helman L.J., DePinho R.A., Merlino G. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat. Med. 2002, 8:1276-1280.
80. Sharpless N.E., Ferguson D.O., O'Hagan R.C., Castrillon D.H., Lee C., Farazi P.A., Alson S., Fleming J., Morton C.C., Frank K., Chin L., Alt F.W., et al. Impaired nonhomologous end-joining provokes soft tissue sarcomas harboring chromosomal translocations, amplifications, and deletions. Mol. Cell 2001, 8:1187-1196.
81. Shuman C., Smith, A.C., Weksberg R. Beckwith-Wiedemann Syndrome. GeneReviews at GeneTests: Medical Genetics Information 2010, Resource (database online), Copyright, University of Washington, Seattle, 1993-2011. Available at Accessed March 21, 2011. http://www.genetests.org.
82. Singh S., Vinson C., Gurley C.M., Nolen G.T., Beggs M.L., Nagarajan R., Wagner E.F., Parham D.M., Peterson C.A. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am. J. Pathol. 2010, 177:2055-2066.
83. Smith A.C., Squire J.A., Thorner P., Zielenska M., Shuman C., Grant R., Chitayat D., Nishikawa J.L., Weksberg R. Association of alveolar rhabdomyosarcoma with the Beckwith-Wiedemann syndrome. Pediatr. Dev. Pathol. 2001, 4:550-558.
84. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., Bridge J.A., Crist W.M., Triche T.J., Barr F.G. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J. Clin. Oncol. 2002, 20:2672-2679.
85. Stratton M.R., Fisher C., Gusterson B.A., Cooper C.S. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989, 49:6324-6327.
86. Sumino Y., Hirata Y., Sato F., Mimata H. Growth mechanism of satellite cells in human urethral rhabdosphincter. Neurourol. Urodyn. 2007, 26:552-561.
87. Takahashi Y., Oda Y., Kawaguchi K., Tamiya S., Yamamoto H., Suita S., Tsuneyoshi M. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol. 2004, 17:660-669.
88. Takayama H., LaRochelle W.J., Sharp R., Otsuka T., Kriebel P., Anver M., Aaronson S.A., Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA 1997, 94:701-706.
89. Taylor A.C., Shu L., Danks M.K., Poquette C.A., Shetty S., Thayer M.J., Houghton P.J., Harris L.C. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med. Pediatr. Oncol. 2000, 35:96-103.
90. Taylor J.G.t., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., Yu Y., Chen Q.R., Shah K., Youngblood V., Fang J., Kim S.Y., et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
91. Tostar U., Malm C.J., Meis-Kindblom J.M., Kindblom L.G., Toftgard R., Unden A.B. Deregulation of the hedgehog signalling pathway: A possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 2006, 208:17-25.
92. Tsumura H., Yoshida T., Saito H., Imanaka-Yoshida K., Suzuki N. Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. Oncogene 2006, 25:7673-7679.
93. Wang Z.Q., Grigoriadis A.E., Mohle-Steinlein U., Wagner E.F. A novel target cell for c-fos-induced oncogenesis: Development of chondrogenic tumours in embryonic stem cell chimeras. EMBO J. 1991, 10:2437-2450.
94. White J.D., Rachel C., Vermeulen R., Davies M., Grounds M.D. The role of p53 in vivo during skeletal muscle post-natal development and regeneration: Studies in p53 knockout mice. Int. J. Dev. Biol. 2002, 46:577-582.
95. Wiggan O., Fadel M.P., Hamel P.A. Pax3 induces cell aggregation and regulates phenotypic mesenchymal-epithelial interconversion. J. Cell Sci. 2002, 115:517-529.
96. Wilke W., Maillet M., Robinson R. H-ras-1 point mutations in soft tissue sarcomas. Mod. Pathol. 1993, 6:129-132.
97. Xia S.J., Pressey J.G., Barr F.G. Molecular pathogenesis of rhabdomyosarcoma. Cancer Biol. Ther. 2002, 1:97-104.